Search

everythinglearnresearchcommunity

for

Search:↓

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

The conversation discusses using dutasteride, both topical and oral, for hair loss in trans men, considering potential side effects like depression and libido issues. The user is exploring options including topical solutions with minoxidil, retinoic acid, and hydrocortisone, and plans to start microneedling.

The user is experiencing severe hair shedding after taking finasteride for three weeks and plans to stop due to gynecomastia symptoms. Stopping finasteride may lead to some hair regrowth, but benefits from the treatment might be lost; topical alternatives are suggested.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

A person is microdosing estrogen for hair loss after finasteride and dutasteride failed, risking feminizing effects. Alternatives like minoxidil, RU58841, or hair transplants are suggested.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Hair loss treatments discussed: GT 20029, Pyrilutamide, Minoxidil, Finasteride, and Dutasteride. Some believe Dutasteride will replace Finasteride.

A 24-year-old shared their successful hair restoration journey, which included a hair transplant in Turkey, dutasteride, and topical minoxidil. They also started testosterone replacement therapy, which improved their quality of life and hair condition, and they now feel confident and satisfied with the results.

Finasteride effectively treated hormonal acne for multiple users, including the original poster. Topical treatments like Winlevi are effective but expensive and not always covered by insurance.

Minoxidil effective for regrowth but causes dryness; finasteride stops hair loss but may affect hormones; dutasteride powerful but reduces libido; RU58841 thickens hair but expensive and risky; dermarolling improves blood flow and results; aminexil overrated and not effective. Dermarolling beneficial with both minoxidil and finasteride.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Users share experiences with Finasteride, mentioning watery semen as a side effect and weighing its importance against maintaining hair.

The user experienced side effects from finasteride and Nutrafol, opting for non-hormonal treatments like minoxidil, exercise, and a healthy lifestyle. Others discussed using Dutasteride, Biotin, and minoxidil with varying success and side effects.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

User stopped using minoxidil due to no growth and greasiness, but experienced hair regrowth after starting HRT with spironolactone and finasteride. Shared before and after photos, showing improvement in hair thickness.

The conversation discusses alternatives to minoxidil and finasteride for hair regrowth, with mentions of essential oils, PRP therapy, and RU58841. The focus is on finding treatments with minimal side effects, especially concerning fertility.

The conversation is about adding a topical anti-androgen to a hair loss treatment regimen that includes dutasteride and oral minoxidil. The user is considering topical finasteride or dutasteride, Nizoral shampoo, KX-826, and topical spironolactone, while avoiding RU58841 due to safety concerns.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The post discusses a user's successful hair recovery using minoxidil, finasteride, and hormone replacement therapy (HRT) with cyproterone acetate and estradiol. The user experienced significant improvement in hair density and hairline recovery.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Finasteride increased libido for some users, with effects normalizing after a few weeks to months. Other treatments mentioned include Dutasteride and Minoxidil.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

The effectiveness of Finasteride/Dutasteride for treating hair loss, and a cautionary tale about potential side effects such as gynecomastia.

The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.